Cargando…

Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations

Baseline locomotion and behavioral traits in the common marmoset Parkinson's disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Kiyoshi, Inoue, Takashi, Hikishima, Keigo, Komaki, Yuji, Kawai, Kenji, Inoue, Ryo, Nishime, Chiyoko, Nishinaka, Eiko, Urano, Koji, Okano, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams and Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964884/
https://www.ncbi.nlm.nih.gov/pubmed/31625972
http://dx.doi.org/10.1097/FBP.0000000000000509
_version_ 1783488541803675648
author Ando, Kiyoshi
Inoue, Takashi
Hikishima, Keigo
Komaki, Yuji
Kawai, Kenji
Inoue, Ryo
Nishime, Chiyoko
Nishinaka, Eiko
Urano, Koji
Okano, Hideyuki
author_facet Ando, Kiyoshi
Inoue, Takashi
Hikishima, Keigo
Komaki, Yuji
Kawai, Kenji
Inoue, Ryo
Nishime, Chiyoko
Nishinaka, Eiko
Urano, Koji
Okano, Hideyuki
author_sort Ando, Kiyoshi
collection PubMed
description Baseline locomotion and behavioral traits in the common marmoset Parkinson's disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free base over three consecutive days was administered subcutaneously to 10 marmosets. Data obtained from these marmosets were compared to pre-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine levels or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine free marmosets. After the single regimen, reduced daily locomotion, a measure of immobility (a primary sign of Parkinsonism), was observed for more than a year. A moving tremor was also observed by visual inspection during this period. When apomorphine (0.13 mg/kg, s.c.) was administered, either right or left circling behavior was observed in a cylindrical chamber in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets, suggestive of unequal neural damage between the two brain hemispheres to different extents. MRI revealed that T1 relaxation time in the right substantia nigra correlated with right circling in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets. Histology was supportive of dopaminergic neural loss in the striatum. These results increase our understanding of the utility and limitations of the Parkinson's disease model in marmosets with a single 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine regimen, and provide reference data for efficacious preclinical evaluations.
format Online
Article
Text
id pubmed-6964884
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams and Wilkins
record_format MEDLINE/PubMed
spelling pubmed-69648842020-02-03 Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations Ando, Kiyoshi Inoue, Takashi Hikishima, Keigo Komaki, Yuji Kawai, Kenji Inoue, Ryo Nishime, Chiyoko Nishinaka, Eiko Urano, Koji Okano, Hideyuki Behav Pharmacol Research Reports Baseline locomotion and behavioral traits in the common marmoset Parkinson's disease model were examined to provide basic information for preclinical evaluations of medical treatments. A single regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine at a cumulative dose of 5 mg/kg as the free base over three consecutive days was administered subcutaneously to 10 marmosets. Data obtained from these marmosets were compared to pre-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine levels or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine free marmosets. After the single regimen, reduced daily locomotion, a measure of immobility (a primary sign of Parkinsonism), was observed for more than a year. A moving tremor was also observed by visual inspection during this period. When apomorphine (0.13 mg/kg, s.c.) was administered, either right or left circling behavior was observed in a cylindrical chamber in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets, suggestive of unequal neural damage between the two brain hemispheres to different extents. MRI revealed that T1 relaxation time in the right substantia nigra correlated with right circling in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine marmosets. Histology was supportive of dopaminergic neural loss in the striatum. These results increase our understanding of the utility and limitations of the Parkinson's disease model in marmosets with a single 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine regimen, and provide reference data for efficacious preclinical evaluations. Lippincott Williams and Wilkins 2020-02 2020-01-10 /pmc/articles/PMC6964884/ /pubmed/31625972 http://dx.doi.org/10.1097/FBP.0000000000000509 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Research Reports
Ando, Kiyoshi
Inoue, Takashi
Hikishima, Keigo
Komaki, Yuji
Kawai, Kenji
Inoue, Ryo
Nishime, Chiyoko
Nishinaka, Eiko
Urano, Koji
Okano, Hideyuki
Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
title Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
title_full Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
title_fullStr Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
title_full_unstemmed Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
title_short Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
title_sort measurement of baseline locomotion and other behavioral traits in a common marmoset model of parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964884/
https://www.ncbi.nlm.nih.gov/pubmed/31625972
http://dx.doi.org/10.1097/FBP.0000000000000509
work_keys_str_mv AT andokiyoshi measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT inouetakashi measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT hikishimakeigo measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT komakiyuji measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT kawaikenji measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT inoueryo measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT nishimechiyoko measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT nishinakaeiko measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT uranokoji measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations
AT okanohideyuki measurementofbaselinelocomotionandotherbehavioraltraitsinacommonmarmosetmodelofparkinsonsdiseaseestablishedbyasingleadministrationregimenof1methyl4phenyl1236tetrahydropyridineprovidingreferencedataforefficaciouspreclinicalevaluations